Spyre Therap Rg
SYRE
USD
STOCK MARKET:
NMS
Closed
 
...
Large gap with delayed quotes
Last quote
08/15/2026 - 02:00:00
Bid
08/14/2026 - 21:59:59
Bid
Volume
Ask
08/14/2026 - 21:59:59
Ask
Volume
103.63
+1.78 ( +1.75% )
103.39
800
103.63
1,700
More information
Analysis by TheScreener
14.08.2026
Evaluation Neutral  
Interest Weak  
Sensibility Middle  
Analysis date: 14.08.2026
Global Evaluation
  Neutral
The stock is classified in the neutral zone since 03.07.2026.
Interest
  Weak
Two stars since 03.07.2026.
Earnings Rev Trend
  Negative
 
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 03.07.2026 at a price of 86.63.
Evaluation
  Strongly overvalued
 
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
  Positive
 
The dividend-adjusted forty day technical trend is positive since 03.07.2026.
4wk Rel Perf
  1.52%
 
The four-week dividend-adjusted overperformance versus SP500 is 1.52%.
Sensibility
  Middle
The stock has been on the moderate-sensitivity level since 03.07.2026.
Bear Market Factor
  Low
On average, the stock has a tendency to minimize the drops in the index by -1.68%.
Bad News Factor
  Low
When the stock's pressure is specific, the market sanction on average is 2.89%.
Mkt Cap in $bn
  9.14
With a market capitalization >$8bn, SPYRE THERAPEUTICS is considered a large-cap stock.
G/PE Ratio
  -1.03
A negative ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) indicates that either the forecasted growth is decelerating (negative annualized growth estimate) or the financial analysts are expecting a loss (negative estimated PE).
LT P/E
  -25.93
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
  -26.64%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
  13
Over the last seven weeks, an average of 13 analysts provided earnings per share estimates.
Dividend Yield
  0.00%
The company is not paying a dividend.
Beta
  127
For 1% of index variation, the stock varies on average by 1.27%.
Correlation
  0.22
Stock movements are strongly independent of index variations.
Value at Risk
  24.87
The value at risk is estimated at USD 24.87. The risk is therefore 24.00%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
  03.07.2026